Legend Biotech (LEGN) Stock: CARVYKTI Revenue Soars 66% in Q4 with 2026 Profit Target

Key Highlights

• CARVYKTI generated $555M in Q4 net trade sales, marking a 66% year-over-year jump worldwide.
• Domestic sales climbed to $420M while overseas revenue surged threefold to $135M.
• Production capabilities are being scaled to 20,000 doses annually with exceptional 97–99% manufacturing success.
• Patient data reveals 50.4-month median progression-free survival in critical cohorts.
• Bio Legend forecasts company-wide profitability by the end of 2026.

Legend Biotech (LEGN) stock experienced a 1.77% decline to $18.80 even as CARVYKTI demonstrated robust worldwide sales traction. The biotechnology firm disclosed $555 million in Q4 net trade sales, representing a 66% annual increase. With CARVYKTI achieving profitability in 2025 and enterprise-level profit anticipated for 2026, the fundamentals support Bio Legend stock’s extended horizon.

Legend Biotech Corporation, LEGN

CARVYKTI Revenue Performance and Geographic Reach

Domestic CARVYKTI net trade sales registered $420 million during Q4, climbing 38% annually and 6% from the previous quarter. Overseas markets contributed $135 million, more than tripling compared to the same period last year, with notable strength in Germany, Spain, and Belgium. Bio Legend stock gains momentum from operational presence across 14 global territories and 294 active treatment centers expanding CARVYKTI’s commercial reach.

The organization has established production infrastructure for 10,000 annual doses and intends to double that capacity to 20,000 units in partnership with Johnson & Johnson. CARVYKTI manufacturing success metrics consistently range between 97% and 99%, guaranteeing dependable worldwide distribution. These operational achievements support escalating demand while bolstering the investment case for Bio Legend stock.

CARVYKTI deployment is progressively shifting toward earlier treatment stages, with 65% of recipients now receiving therapy between second and fourth lines. Spanish clinicians report 70% to 75% adoption in earlier-line settings, signaling a broader international pattern. This upstream utilization trend may enhance therapeutic outcomes and sustain CARVYKTI’s revenue trajectory.

Clinical Evidence and Treatment Protocol Advances

Extended follow-up from CARTITUDE-1 and CARTITUDE-4 studies demonstrated median progression-free survival of 50.4 months among triple-class-exposed participants. Standard-risk cohorts maintained 80% progression-free status beyond 2.5 years, with 93% survival rates among patients remaining progression-free at the one-year mark. These findings validate CARVYKTI’s long-term efficacy and strengthen the scientific foundation for Bio Legend stock.

Contemporary patient management protocols now prioritize bridging treatments to reduce disease burden and minimize neurotoxic complications. Clinical evidence confirms zero instances of colitis or Parkinsonism among patients receiving bridging therapy before CARVYKTI administration. Continuous research efforts and evolving NCCN recommendations further refine patient safety protocols and therapeutic effectiveness.

Bio Legend also unveiled Lucar-G39D findings, an off-the-shelf CAR T-cell treatment for relapsed or refractory B-cell non-Hodgkin’s lymphoma. Preliminary outcomes showed acceptable safety profiles alongside promising anticancer responses. Diversifying the pipeline beyond CARVYKTI creates additional growth avenues for Bio Legend stock.

Quarterly Financials and Profit Timeline

Legend Biotech disclosed $306 million in fourth-quarter revenue, representing a 64% year-over-year advance, accompanied by a 61% gross margin. Operating losses narrowed to roughly $20 million, while adjusted net income reached $2.5 million versus a $59 million deficit in the prior-year quarter. Bio Legend stock benefits from management’s explicit roadmap toward company-wide profitability in 2026.

Research and development expenditures declined 3% as BCMA frontline studies matured, whereas selling, general, and administrative costs increased 22% reflecting commercial infrastructure investments. The company maintained $949 million in cash, cash equivalents, and time deposits at year-end, with Q4 operating cash consumption limited to $12 million. Sequential quarterly advances and planned capacity expansions reinforce Bio Legend stock’s strategic positioning.

Executives anticipate approximately 50% top-line CARVYKTI expansion during 2026, propelled by worldwide adoption and treatment center proliferation. In vivo CAR T innovation and non-viral delivery platform exploration augment existing oncology and hematology initiatives. Collectively, Bio Legend stock trends align with vigorous sales momentum, sustained clinical performance, and broadening international presence.

The post Legend Biotech (LEGN) Stock: CARVYKTI Revenue Soars 66% in Q4 with 2026 Profit Target appeared first on Blockonomi.